Sign up Australia
Proactive Investors - Run By Investors For Investors

Medical Australia bags $4 million to expand animal stem cell company

Medical Australia bags $4 million to expand animal stem cell company

Medical Australia (ASX: MLA) will trade firmer today after completing a $4 million placement at $0.20 per share via issue of 20,000,000 new shares issued to two strategic investors with a successful history in the healthcare sector.

Notably, the $0.20 price tag is at a premium to the prevailing share price, signifying additional confidence in the company's growth prospects.

Windfall Trust and Walker Group Holdings have subscribed for 10,000,000 shares each.

The placement is the final step in completing the acquisition and integration of animal stem cell therapy and regenerative medicine company, MediVet.

This is a company-transforming transaction, and these new funds will allow Medical to take full advantage of the growth opportunities that the MediVet business and traditional human healthcare markets represent.

In particular there is scope for significant growth in the United States, where there are over 27,000 veterinary clinics.

MediVet’s range of regenerative medicine technologies is rapidly gaining acceptance in the equine and horse racing industries, representing another solid growth platform.

Medical has also finalised the issue of 36,666,667 shares to the Vendors of MediVet, and now holds 60.5% of MediVet America, and 100% of MediVet Pty Ltd which encompasses Canada, USA, Great Britain, Continental Europe, the Middle East, Australia and the Asia Pacific Region.

The integration of Medical and MediVet into one company is well advanced with the businesses now operating at one
location in Lidcombe, New South Wales.

Medical Australia is capitalised at around $20 million post acquisition, based on the current share price.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Register here to be notified of future MLA Company articles
View full MLA profile View Profile

Medical Australia Timeline

Related Articles

June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Genetic data
July 12 2016
Drug discovery company snaps up software system for "non-material" sum

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use